Kolon Life Science signs $200M supply deal for osteoarthritis drug Invossa-K

Kolon Life Science signed a 230 billion won ($200 million) contract to supply its osteoarthritis drug Invossa-K to China Life Medical Centre in Hainan Province, China. The contract was announced on July 18, 2018.

“Kolon Life Science has signed a 230 billion won ($200 million) contract to export its osteoarthritis drug Invossa-K to China Life Medical Centre and Hainan Province.”biz.heraldcorp.com

• 2 sources
• biz.heraldcorp.com코오롱생명과학(102940), China Life Medical Centre과 1726.9억원 규모의 단일판매ㆍ공급계약체결 - 헤럴드경제HeRoJul 17, 2018
• pulse.mk.co.krKolon Life Science inks $200 mn deal to export osteoarthritis to China - 매일경제 영문뉴스 펄스(Pulse)Jul 18, 2018

Summarized from public sources; check the original articles before acting on it.